Abivax (AAVXF) Long-Term Debt Issuances (2024)

Abivax (AAVXF) posted Long-Term Debt Issuances of $51.2 billion for Q4 2024, up 7767445.99% on a QoQ basis from -$658931.7 in Q3 2024.

Analysis

Abivax (AAVXF) Long-Term Debt Issuances (2024) Analysis & Trends

Abivax has reported Long-Term Debt Issuances for 1 years, with the latest figure at $51.2 billion in Q4 2024.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $51.2 billion in Q4 2024; TTM through Dec 2025 was $51.2 billion, a 0.1% change from a year earlier, with the FY2024 full-year figure at $51.2 billion, changed N/A from the prior year.
Long-Term Debt Issuances was $51.2 billion for Q4 2024 at Abivax, up from -$658931.7 in the prior quarter.
The five-year high for Long-Term Debt Issuances was $51.2 billion in Q4 2024, with the low at -$658931.7 in Q3 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Amgen	211.50 Bn	197.51 Bn	7.24 Bn	-
2	Gilead Sciences	181.29 Bn	178.11 Bn	6.22 Bn	1.32 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.55 Bn	74.56 Bn	3.93 Bn	-
5	Argenx Se	61.65 Bn	56.47 Bn	1.37 Bn	-
6	Moderna	54.65 Bn	49.52 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	34.18 Bn	30.87 Bn	992.69 Mn	-
8	Biogen	31.36 Bn	30.07 Bn	1.96 Bn	-
9	Roivant Sciences	30.01 Bn	30.01 Bn	1.16 Mn	-
10	Abivax	10.92 Bn	10.92 Bn	-	-

Historic Data

Download Data